News and Trends 11 Jan 2022 Sanofi Joins AI Gold Rush in €4.6B Drug Discovery Pact with Exscientia As big pharma companies flock to drug discovery collaborations with artificial intelligence (AI) firms, the French giant Sanofi has sealed a €4.6B deal with the UK AI player Exscientia to develop oncology and immunology treatments. According to the deal’s terms, the partners will develop up to 15 small molecule drugs to treat cancer and immunological […] January 11, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 10 Jan 2022 Leveraging Physics and Quantum Computing to Accelerate Drug Discovery Novel computational techniques are revolutionizing the way we discover new drugs. Robert Marino, CEO and co-founder of Qubit Pharmaceuticals, discusses the potential of physics to accelerate drug discovery. Paris-based Qubit Pharmaceuticals was established in 2020 to commercialize the work of leading researchers in the computational chemistry space. This field uses computer modeling to predict how […] January 10, 2022 - 9 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 7 Oct 2021 Exscientia IPO Attracts Tech Investor Bets to AI Drug Discovery Exscientia’s lucrative entry onto the Nasdaq last week demonstrated investors are still excited by efforts to use artificial intelligence to fuel drug discovery, with global tech investors often taking the lead. The Oxford, UK-based company Exscientia has one of the most mature artificial intelligence (AI)-focused drug discovery pipelines, alongside companies like BenevolentAI in the UK, […] October 7, 2021 - 5 minutesmins - By Mark Zipkin Share WhatsApp Twitter Linkedin Email
Sponsored by Charles River 28 Sep 2021 Artificial Intelligence: A Road to Faster and Better Drug Discovery? Artificial intelligence (AI) has become a part of everyday modern life and continues to generate excitement. In this article, we will take a look at how biotechs are advancing into AI-facilitated early drug design, its real-world outcomes so far, and whether it is living up to its potential in the life science industry. AI enables […] September 28, 2021 - 6 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Opinion 31 Aug 2021 Cloud Foundations for R&D: Designing the Future of Life Sciences In recent years, artificial intelligence has been hailed as the next big thing in drug discovery. But to leverage the full potential of this technology the life sciences industry first needs to pay attention to experimental design and data collection. We embrace the latest digital technologies to enhance almost everything in our daily lives—from how […] August 31, 2021 - 7 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
In Depth 7 Jun 2021 The Post-Covid Future of AI for Drug Development With the global Covid-19 outbreak in early 2020, pharma companies and biotechs have increasingly turned to artificial intelligence to improve precision and speed in drug development. Artificial intelligence (AI), the ability of machines to learn from new input, is a broad term for a range of computing methods. Recommendation engines used by online shopping or […] June 7, 2021 - 11 minutesmins - By Matthew Williams Share WhatsApp Twitter Linkedin Email
Interview 22 Feb 2021 How Automation Can Augment Drug Discovery Research Robotics and artificial intelligence are rapidly changing the way we discover drugs. Martin-Immanuel Bittner, CEO and co-founder of Arctoris, discusses the benefits and challenges of introducing automation in drug discovery efforts. The Oxford-based startup Arctoris was established in 2016 with the objective of offering remote access to automated drug discovery. At a time when researchers […] February 22, 2021 - 8 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
Startup Scout 27 Sep 2019 This Biotech Can Screen CAR T-Cells Using Only Light and Microfluidics Based in Cambridge, UK, Lightcast Discovery is developing microfluidics technology that automates cell screening experiments by using lasers. Mission: To automate cell screening experiments, such as those used when screening CAR T-cell immunotherapies. This would let companies test therapies in complex cell experiments, such as cell-to-cell interactions, which are difficult with traditional drug-screening tools. Cell […] September 27, 2019 - 3 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
Interview 23 May 2019 Why Clinical Trial Design Can Make or Break Your Company Andreas Wallnöfer spent over 20 years working on drug development at Roche before moving to BioMedPartners to apply his expertise to biotech investment. At our recent Labiotech Refresh event in Zurich, he explained why good clinical trial design can be key to a biotech’s success. Wallnöfer was one of the pioneers of ‘proof of concept’ […] May 23, 2019 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
Startup Scout 18 Jan 2019 This Biotech Turns Rejected Organs Into Drug Testing Models Engitix, a spinout from University College London, makes accurate disease models from human tissue that include the extracellular matrix from outside of the cells, an often overlooked but essential factor in the way cells behave inside our bodies. Mission: To make disease models in the lab that include the extracellular matrix, making them more […] January 18, 2019 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 7 Jan 2019 AI Drug Discovery Company Raises €23M and Signs with Roche Oxford-based Exscientia has closed a €23M ($26M) Series B round and announced a partnership with Roche worth up to €60M. Exscientia has developed an artificial intelligence platform to boost drug discovery in pharma and biotech. “We can reduce at least 4- to 5-fold the time and cost of drug discovery as compared to the industry […] January 7, 2019 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2018 More Brexit Bad News: EMA Pulls Contracts Early From UK Regulatory Body The European Medicines Agency (EMA) has pulled all contracts with the UK’s medical regulation body ahead of the UK withdrawing from the EU next year. Until 2018, the EMA has relied on the UK Medicines & Healthcare products Regulatory Agency (MHRA) to assess 20–30% of its drugs on a contract basis, work worth approximately €15.6M […] September 6, 2018 - 2 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email